Prostate cancer drug combination could prevent treatment resistance

Using two prostate cancer drugs in combination could help to prevent resistance to treatment from building up, a UK study suggests.

Prostate cancer: combination therapy could widen treatment access (Photograph: SPL)
Prostate cancer: combination therapy could widen treatment access (Photograph: SPL)

Researchers believe the approach could mean more patients benefiting from drug treatment and patients responding to therapy for longer.

Dr Gerhardt Attard and colleagues from the Royal Marsden NHS Foundation Trust in London examined why men develop resistance to the hormone-blocking treatment with abiraterone.

The study looked at the possibility that drugs often given alongside abiraterone to control side-effects contribute to the development of resistance.

In cell-based tests, the team of researchers found steroids and other drugs given to treat side-effects contribute to resistance to abiraterone by activating mutations in the hormone-receptor gene.

The team found that it was possible to block this activation using combination treatment with MDV3100, another hormone blocking treatment for prostate cancer.

Commenting on the findings, Dr Attard said: ‘Abiraterone is an effective treatment for the majority of men with advanced prostate cancer, but sadly they all eventually develop resistance. Our study suggests we should combine prostate cancer drugs rather than giving them sequentially.

‘If the results hold true in patients, this could delay drug resistance and increase the number of men who benefit. Trials are being planned to test abiraterone and MDV3100.’

Dr Attard and his colleagues also suggested that further studies could examine other approaches to improving treatment responses, such as using higher doses of abiraterone taken with food.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...